CBD and CBG could provide the first-ever treatment for fatty liver disease
The medical world is buzzing following a groundbreaking study from the Hebrew University of Jerusalem. Researchers have uncovered that two non-psychoactive compounds, CBD and CBG, could provide the first-ever drug treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), commonly known as fatty liver disease.
At CBD Seed Europe, we have long advocated for the diverse potential of the hemp plant beyond simple wellness. This peer-reviewed research, recently published in The British Journal of Pharmacology, confirms that the synergy of cannabinoids offers a sophisticated biological "toolkit" for metabolic health.
The Silent Crisis: 1 in 3 Adults at Risk
Fatty liver disease is the most common liver disorder globally, yet despite its prevalence, there is currently no approved drug to treat it. As obesity rates rise, the liver is forced to store excess fat, leading to inflammation, scarring, and eventual functional failure.
While lifestyle changes can help, a pharmacological solution has been the "holy grail" for researchers. According to Prof. Yossi Tam, Director of the Multidisciplinary Center for Cannabinoid Research, the answer may lie in how cannabinoids interact with the body's internal energy management.
How CBD and CBG "Remodel" the Liver
The study, conducted on models of diet-induced obesity, revealed that the combination of CBD and CBG doesn't just reduce fat—it fundamentally changes how the organ functions internally.
The researchers identified two key biological mechanisms:
- The "Backup Battery" (Phosphocreatine): High-fat diets deplete the liver’s energy reserves. CBD and CBG were found to increase levels of phosphocreatine, an energy molecule that acts like a backup battery, helping the liver cells recover and recharge.
- The "Cleaning Crew" (Cathepsins): The treatment restores the activity of specific enzymes that act as a cellular cleaning crew. This allows the liver to effectively clear out harmful waste and dangerous fats like ceramides, which are known to cause insulin resistance.
"The study portends enormous public health significance... providing an apparently safe and effective treatment option based on two cannabis plant compounds." — Dr. Ethan Russo, CEO of CReDO Science.
Why the CBD + CBG Combination is the Future
The most novel aspect of this research is the synergy between CBD and CBG. While CBD is well-known for reducing food consumption and weight, the researchers were surprised to find that CBG significantly reduced body fat mass and lowered total cholesterol levels.
By combining these two non-intoxicating compounds, the team at Hebrew University has patented a formulation that targets metabolic syndrome from multiple angles. This discovery paves the way for human clinical trials and, potentially, the world’s first drug for a disease that affects billions.
Our Perspective: It All Starts with the Seed
As this research moves toward the clinic, the importance of stable, high-quality genetics cannot be overstated. To produce pharmaceutical-grade extracts of CBD and CBG, the industry requires specialized hemp varieties bred for specific cannabinoid profiles.
At CBD Seed Europe, we are inspired by these scientific leaps. They reinforce our commitment to providing the elite genetics necessary to fuel the next generation of cannabinoid-based medicines.
Source: The Times of Israel
